Oncolytics Biotech® to Present Compelling New Efficacy and Safety Data in Anal and Pancreatic Cancers at 2025 ASCO GI Symposium

Core Insights - Oncolytics Biotech's pelareorep shows significant improvement in combination therapy for anal cancer patients compared to checkpoint inhibitors alone [1][2] - The therapy also demonstrates a strong safety profile when combined with a new chemotherapy regimen in pancreatic cancer patients [1][2] Summary by Category Efficacy in Anal Cancer - Pelareorep combined with atezolizumab continues to outperform historical control trials in relapsed anal cancer, with a complete response lasting beyond 12 months [2][4] - In a cohort of 12 evaluable patients, 4 achieved a partial response, resulting in an objective response rate of 33%, which is notably higher than the historical response rates of 10-24% for checkpoint inhibitors alone [4] Safety Profile - No safety concerns have been reported with the pelareorep and atezolizumab combination therapy, indicating a manageable safety profile [4] - Tumor-infiltrating lymphocyte (TIL) clonal expansion was observed in responding patients, suggesting a positive immune response [4] Pancreatic Cancer Developments - Pelareorep has shown promising efficacy signals when combined with gemcitabine, nab-paclitaxel, and atezolizumab in metastatic pancreatic ductal adenocarcinoma (PDAC) [7] - A new cohort in the GOBLET study is evaluating pelareorep with modified FOLFIRINOX, with safety data reviewed positively by regulatory bodies, allowing for continued patient enrollment [7][5] GOBLET Study Overview - The GOBLET study is a phase 1/2 trial exploring treatment combinations with pelareorep in advanced or metastatic gastrointestinal tumors, with co-primary endpoints focusing on objective response rate and safety [10] - The study is being conducted at 17 centers in Germany, with the potential for cohorts meeting efficacy criteria to advance to further stages [11]